Moderna, Inc. MRNA NASDAQ

Moderna, Inc. (MRNA) reported total assets of $12.34B and total liabilities of $3.69B for fiscal year 2025, resulting in total equity of $8.65B.

The company held $5.8B in cash and short-term investments. Total debt stood at $1.92B, with net debt of $-679M. The Debt-to-Equity (D/E) ratio was 0.22 (conservative).

Current ratio is 3.29, indicating strong short-term liquidity.

Criteria supported by this page:

• HEALTH (100/100, Pass) — Debt-to-Equity of 0.22, current ratio of 3.29 — balance sheet is strong
• MOAT (65/100) — Total assets $12.34B and equity $8.65B support the company's competitive scale
• VALUE (63/100) — Debt-to-Equity 0.22 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 42/100 with 2/7 criteria passed.

VRTX

Vertex Pharmaceuticals Incorporated

$444.28

+0.96%

KRYS

Krystal Biotech, Inc.

$270.00

+0.97%

RETA

Reata Pharmaceuticals, Inc.

$172.36

+0.02%

BEAM

Beam Therapeutics Inc.

$30.30

+0.40%

NTLA

Intellia Therapeutics, Inc.

$14.78

+3.65%

NVAX

Novavax, Inc.

$8.39

+3.45%

CVAC

CureVac N.V.

$4.66

+0.00%

DNA

Ginkgo Bioworks Holdings, Inc.

$7.72

+15.57%